FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL		
OMB Number:	3235-0287	
Estimated average burden		
hours per response:	0.5	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

# Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person\* (Check all applicable) Athira Pharma, Inc. [ ATHA ] JOHNSON JAMES A X Director 10% Owner Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) below) below) (Last) (First) (Middle) 05/20/2022 C/O ATHIRA PHARMA, INC. 18706 NORTH CREEK PARKWAY, SUITE 104 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) (Street) Form filed by One Reporting Person **BOTHELL** 98011 WA Form filed by More than One Reporting (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature Securities Beneficially of Indirect Beneficial Transaction (Month/Day/Year) (D) or Indirect 5) if any (Month/Day/Year) Code (Instr. 8) Owned Following Reported (I) (Instr. 4) Ownership (Instr. 4) (A) or (D) Transaction(s) (Instr. 3 and 4) Price Amount Code Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and Amount 8. Price of 9. Number of 10. 11. Nature Date (Month/Day/Year) Conversion Execution Date, Expiration Date (Month/Day/Year) derivative Securities Ownership of Indirect Beneficial Transaction of Securities Underlying Derivative Security or Exercise Code (Instr. Security if any Form: Price of Derivative Security (Instr. 3) (Month/Day/Year) 8) Securities Derivative Security (Instr. 3 and 4) (Instr. 5) Beneficially Direct (D) Ownership Acquired (A) or Disposed Owned Following or Indirect (I) (Instr. 4) (Instr. 4) Reported of (D) (Instr 3, 4 and 5) Transaction(s) (Instr. 4) Amount or Number Date Expiration Date Code (A) (D) Exercisable Title Shares Stock

#### **Explanation of Responses:**

\$8.93

1. The shares subject to the option will vest on the earlier of (i) May 20, 2023, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 20, 2022. The option reported was granted pursuant to the terms of the Issuer's outside director compensation policy

13,87

05/20/2022

### Remarks:

Option

Buy)

(Right to

/s/ Glenna Mileson, attorney-in-

13,871

fact on behalf of James A. 05/27/2022

\$0.00

13,871

D

**Johnson** 

Common

Stock

05/19/2032

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.